November 17, 2026, 12pm-1pm ET
From the lab to the community: Familial Alzheimer’s disease in Jalisco, Mexico
Speakers: Dr. Angélica Zuno Reyes and Frida Rosales Leycegui
Autosomal dominant Alzheimer’s disease (ADAD) is a rare, inherited form of early- onset Alzheimer’s disease (AD) caused by nearly fully penetrant mutations, affecting families for generations. Because carriers of a causal mutation are born with a genetic alteration that virtually guarantees the onset of symptoms, often at a predictable age, ADAD offers a unique opportunity to study the disease before it manifests and throughout its stages, and to design preventive interventions for AD and related dementias. In Jalisco, Mexico, two large ADAD populations have been identified, carrying the PSEN1A431E (“Jalisco mutation”) or the APPV717I mutation.
This talk presents the work of a binational, multidisciplinary team at the Universidad de Guadalajara and the University of Southern California. Through an ongoing research protocol, the team has reconstructed historical pedigrees and conducted longitudinal functional, clinical, and cognitive assessments, as well as biosample collection, among other activities. Beyond the laboratory, we describe how community meetings and events, the development and implementation of genetic counseling programs, and social work and caregiving support have sustained long-term participant adherence, and how participants have become active partners in the research. Finally, we discuss future directions in neuroimaging, biomarkers, and clinical trials, and the role of community engagement in making ADAD research accessible and useful to the families it serves.
Please note that registration is required to attend. Click here to register.
December 15, 2026, 12pm-1pm ET
Genetic, pathologic and hormonal contributions to psychosis in Alzheimer’s disease
Speaker: Corinne Fischer
This presentation will examine putative mechanisms underlying psychosis in Alzheimer’s disease and how sex, APOE4 status and brain pathology may play a role. Specifically, we will examine how APOE4 status interacts with sex and pathology to determine psychotic phenotypes and how this knowledge may inform treatment. We will also examine the protective role of estrogen therapy in Alzheimer’s disease-related psychosis.
Please note that registration is required to attend. Click here to register.
Past webinars
What are you looking for?
SYNERGIC Trial: The first Canadian multidomain intervention trial to improve cognition in Mild Cognitive Impairment
October 31, 2023
Results of ENGAGE trial and next steps
October 3, 2023
New features and data querying workshop
September 19, 2023
Food for thought: The role of dietary intake and nutrition risk in cognitive health among older adults
September 5, 2023
Creative connections: The CCNA training program in phase II
June 27, 2023
The impact of Canada’s pivotal work in dementia diagnosis and care in primary care settings – Will governments and specialist clinicians engage?
June 13, 2023
Amyloid clearance by amyloidolytic activity
May 30, 2023
Selective immunotherapies for Alzheimer’s disease and synucleinopathies
April 25, 2023
An honest conversation on building meaningful engagement with diverse communities in dementia research
March 23, 2023
Understanding stigma against dementia during COVID-19: Lived Experience and Social Media Research
January 18, 2023
Cohesion, At-homeness, and Playfulness (CAP): A place-based model to prevent cognitive decline in the community
November 30, 2022
Staging Alzheimer’s disease in vivo
August 15, 2022






